| |
Accelerate miRNA biomarker discoveries with our genomics services
Learn how 
|
|
Today's Big NewsSep 26, 2022 |
While the healthcare industry continues to grapple with a lack of racial and gender diversity at its highest levels of leadership, Fierce Healthcare aims to shine a spotlight on some of the critical contributions made by people of color across health systems, physicians' offices, health tech, research and insurance, with its list of the 10 most influential minority executives for 2022. A lot has changed since Fierce Pharma last ranked the most productive biopharma companies in 2016—a worldwide pandemic on one hand, and some megamergers in the other. But overall its list has shown improvements, with nine out of the top 10 logging more than $1 million in revenue per employee, compared with only four companies clearing that bar five years ago. T-cell engagers remain a hot therapeutic target for Big Pharma, and now Seagen is the latest to want in on the action. The company has inked a deal worth up to $700 million with LavaTherapeutics. - Conor Hale |
|
Tuesday, October 4, 2022 | 1pm ET / 10am PT This panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture. Register now. 
|
|
| By Heather Landi We are honoring leaders who have made a measurable impact on healthcare in the past year and have a demonstrated track record in paving the way forward for others. These leaders have shown examples of innovation, passion and ingenuity. |
|
|
|
By Angus Liu,Zoey Becker,Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky A lot has changed since we last ranked the most productive biopharma companies with numbers from 2016. Two firms lost their status as standalone companies while boosting their acquirers' positions. This year's ranking also unsurprisingly includes COVID-19 superstars and a couple Big Biotechs. |
By James Waldron T-cell engagers remain a hot therapy area for Lava Therapeutics and now Seagen is the latest big pharma that wants in on the action. |
By Conor Hale Smith+Nephew announced that it conducted its first robotically guided revision procedures in patients who have undergone total knee replacements, using its Cori surgical system. |
|
Tuesday, October 4, 2022 | 2pm ET / 11am PT In this webinar we will cover the challenges that this collaboration aims to solve and how the partnership is poised to enable significant scientific outcomes. We will also take your questions live about this exciting advancement. Register now. 
|
|
By Kevin Dunleavy Several measures in the newly signed Inflation Reduction Act will target drug prices. While analysts at Morningstar figure that overall biopharma revenues will take a 2% hit, some companies will be affected more than others. Those more negatively impacted will be Novo Nordisk, Gilead, Bristol Myers Squibb, AstraZeneca and AbbVie. Others such as Pfizer, Merck, Roche and Novartis will not be nearly as exposed, Morningstar says. |
By Frank Diamond Data from two preprint studies offer some inkling of what challenges the latest COVID-19 variant brings. |
By James Waldron European countries' decisions to backtrack on their large orders of Valneva’s COVID-19 vaccine appeared to have sunk the company’s hopes of developing a successor shot. But the French biotech is now teasing that it is in partnering talks it hopes will give it the financial security it needs to pursue this ambition. |
By Andrea Park It doesn’t take a soothsayer to see what’s on the horizon for Seer Medical. |
By Angus Liu While Daiichi Sankyo has been focusing on a stable of antibody-drug conjugates, the Japanese company has won a global first in a blood cancer area that Pfizer is also targeting. |
By Dave Muoio Despite an industrywide labor shortage, provider organizations say rising expenses and pandemic disruptions are to blame for service cuts, shutdowns and layoffs. |
By Nick Paul Taylor Mereo BioPharma’s attempt to appease Rubric Capital Management has failed, with the activist investor rejecting an offer to gain a seat on the board and continuing to push for bigger changes to the biotech. |
By Andrea Park Radar technology is used to track vehicles, measure driving speeds, forecast weather changes and, now, to remotely monitor the severity and progression of Parkinson’s disease. |
By Kevin Dunleavy Astellas got good news and bad in its attempt to keep Pfizer's Hospira from launching its generic version of Lexiscan. While the court granted Astellas an interim injunction which prevents Hospira from launching its copycat until Oct. 5, it also rejected the company’s bid to prevent the launch until the case works its way through U.S. appeals court. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we'll discuss how two Big Pharma companies, GSK and Takeda, made moves this week to bolster their environmental sustainability efforts. We'll discuss their strategies and what we can expect for the future. |
|
|---|
|
|
|
Wednesday, October 5, 2022 | 11am ET / 8am PT This webinar will cover the needs and challenges of precision medicine from a clinical perspective, and present the economic values of employing a single cell technology for better patient stratification. Register now. 
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
